JAN 2021

WHITE PAPER

Acute Muscle Spasms of the Back

Overview of Muscle Spasm Clinical Features & Presentation

Key Highlights: Acute muscle spasms of the back are sudden, sustained involuntary contractions of muscles or muscle groups localized within the spine. During a lifetime, approximately 84% of US adults (175 million) experience musculoskeletal spasms. A review of muscle spasms and clinical features and presentation. 

SEP 11-13, 2020

POSTER #75

Tolperisone for Acute Muscle Spasm: Dose-Ranging STAR Study

Authors:

 

Srinivas Nalamachu, MD; Randall Kaye, MD; Joseph Pergolizzi, MD

 

Key Highlights: Tolperisone dose of 200 mg TID may be a promising treatment for the management of acute muscle spasm without the somnolence typically experienced with skeletal muscle relaxants.

NOV 24, 2020

PUBLICATION

Tolperisone for the Treatment of Acute Muscle Spasm of the Back: Results From the Dose-Ranging Phase 2 STAR Study (NCT03802565)

Authors:

Srinivas Nalamachu, Joseph Pergolizzi, Randall Kaye

Key Highlights: Tolperisone 200 mg TID may be a promising treatment for management of acute muscle spasm, without the somnolence typically associated with SMRs. 

SEP 5, 2020

ARTICLE

Novel Form of Muscle Relaxant Shows Benefit

Tolperisone may help pain from acute back spasms without causing drowsiness

Authors:

 

Judy George, Senior Staff Writer, MedPage Today September 5, 2020

Key Highlights: Tolperisone, a centrally-acting muscle relaxant, may treat symptoms of acute muscle spasms without the sleepiness and cognitive effects associated with other skeletal muscle relaxants.

SEP 11-13, 2020

POSTER #65

Tolperisone 100 and 200 mg Three Times Daily (TID) for Acute Muscle Spasm of the Back: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase 3 Study

Authors:

 

Randall Kaye, MD; Henry Riordan, PhD; Srinivas Nalamachu, MD; Joseph Pergolizzi, MD; Sanam Ara Vaughan

Key Highlights: Approximately 750 subjects are planned to be enrolled at about 60 clinical sites in the United States, with the first subject expected to be enrolled in Fall 2020. A second replicate Phase 3 study will be initiated at a later date.

FEB 3, 2020

PUBLICATION

DRIVING STUDY

 

An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine

Authors:

 

Judy Caron PhD; Randall Kaye MD; Thomas Wessel MD, PhD; Amy Halseth PhD; Gary Kay PhD

 

What is new and conclusion: Subjects who received tolperisone (150 mg TID) experienced no impact on various measures of driving, self-reported sleepiness and cognition measures compared to placebo, in contrast to those who received the widely used muscle relaxant cyclobenzaprine (10 mg TID).

CONTACT NEURANA

4370 La Jolla Village Drive
Suite 860
San Diego, CA 92122
United States

contact@neuranapharma.com

© 2019 Neurana Pharmaceuticals. All Rights Reserved.